Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Baclofen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Baclofen | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Baclofen | DRUG | Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks. |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Diagnosis of alcohol dependence according to ICD-10 (International Classification of Mental and Behavioural Disorders, 10th revision) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th revision) criteria * An alcohol intake of at least two heavy drinking da...
Baclofen is an investigational small molecule being studied for the treatment of alcohol dependence. In a Phase 2 clinical trial, it was evaluated in 56 patients with alcohol dependence. The trial was randomized, double-blind, and placebo-controlled, and it has been completed.
Pulmonx Corporation (NASDAQ: LUNG) is the developer of Baclofen for the treatment of alcohol dependence. The company conducted a Phase 2 clinical trial of the drug in this indication.
Baclofen is in Phase 2 clinical development for alcohol dependence. The Phase 2 trial has been completed. Baclofen is an investigational drug for this indication and is not approved for alcohol dependence.
Baclofen has been studied in one completed Phase 2 clinical trial, identified as NCT01266655, titled "Baclofen for the Treatment of Alcohol Dependence." The trial enrolled 56 participants in Germany and was randomized, double-blind, and placebo-controlled.
Baclofen is the generic name for a drug that is also known by the brand name Lioresal. In the context of alcohol dependence, Baclofen is being studied as an investigational treatment, and it is not approved for this use.